>
Switch to:

Allergy Therapeutics Interest Coverage

: 0 (At Loss) (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Allergy Therapeutics's Operating Income for the six months ended in Jun. 2021 was $-16.5 Mil. Allergy Therapeutics's Interest Expense for the six months ended in Jun. 2021 was $-0.3 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Allergy Therapeutics's Interest Coverage or its related term are showing as below:

OTCPK:AGYTF' s Interest Coverage Range Over the Past 10 Years
Min: 0.65   Med: 3.93   Max: 21.85
Current: 8.21

0.65
21.85

OTCPK:AGYTF's Interest Coverage is ranked lower than
68% of the 645 Companies
in the Drug Manufacturers industry.

( Industry Median: 19.27 vs. OTCPK:AGYTF: 8.21 )

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Allergy Therapeutics Interest Coverage Historical Data

The historical data trend for Allergy Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Interest Coverage
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 21.85 16.49 8.21

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Interest Coverage Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 54.96 - 65.20 -

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics Interest Coverage Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Interest Coverage falls into.



Allergy Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt.


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Allergy Therapeutics's Interest Coverage for the fiscal year that ended in Jun. 2021 is calculated as

Here, for the fiscal year that ended in Jun. 2021, Allergy Therapeutics's Interest Expense was $-0.7 Mil. Its Operating Income was $5.7 Mil. And its Long-Term Debt & Capital Lease Obligation was $13.2 Mil.

Interest Coverage=-1* Operating Income (A: Jun. 2021 )/Interest Expense (A: Jun. 2021 )
=-1*5.6535764375877/-0.68863955119215
=8.21

Allergy Therapeutics's Interest Coverage for the quarter that ended in Jun. 2021 is calculated as

Here, for the six months ended in Jun. 2021, Allergy Therapeutics's Interest Expense was $-0.3 Mil. Its Operating Income was $-16.5 Mil. And its Long-Term Debt & Capital Lease Obligation was $13.2 Mil.

Allergy Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Allergy Therapeutics  (OTCPK:AGYTF) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Allergy Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)